All In Biotech

NDA 021438 · Ani Pharms

Innopran Xl

Propranolol Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Mar 12, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

392

63 Phase 3, 46 recruiting

FAERS reports

11,452

7,760 serious, 1,483 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2026.

INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood...

Mechanism: The mechanism of the antihypertensive effect of propranolol has not been established. Among factors that contribute to the antihypertensive action are: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use. Effects of propranolol on plasma volume appear to be minor and somewhat variable.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 12, 2003 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterLabel
2 products under this application
  • INNOPRAN XL · PROPRANOLOL HYDROCHLORIDE 80MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE BX
  • INNOPRAN XL · PROPRANOLOL HYDROCHLORIDE 120MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE BX

Clinical trials

Interventional ClinicalTrials.gov studies with "Propranolol" as an intervention, any sponsor and status, largest first.

All 392 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,808
  • drug ineffective1,270
  • nausea925
  • product use in unapproved indication877
  • product use issue870
  • headache801
  • fatigue776
  • toxicity to various agents694
  • diarrhoea630
  • drug intolerance598
  • dyspnoea568
  • dizziness555

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004101
2005169
2006128
2007100
200882
2009154
2010178
2011172
2012212
2013145
2014146
2015153
2016232
2017250
2018375
2019401
2020579
2021875
20221,304
20231,480
20241,877
20251,270
20261,069

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Innopran XL (Propranolol HCl)

2024 spending

$2.7M

Beneficiaries

170

584 claims

Per beneficiary

$16,004

$70.91 per unit

View as table
YearSpending
2020$3,035,573
2021$3,171,762
2022$3,124,222
2023$3,126,929
2024$2,720,762

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,504 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.